Business Context and Reporting Period
This Form 8-K is filed by Daré Bioscience, Inc. (Nasdaq: DARE) on April 11, 2025, reporting an event that occurred on April 9, 2025. The filing addresses the company's status regarding compliance with Nasdaq continued listing requirements.
Key Financial Metrics
This filing does not contain specific financial statements, revenue, profit, or cash flow data. The primary financial metric referenced is the Stockholders' Equity Rule under Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5 million. The company has not been in compliance with this rule since August 2024.
Material Changes and Events
- Nasdaq Extension Granted: The Nasdaq Hearings Panel granted Daré Bioscience an extension until August 12, 2025, to demonstrate compliance with Listing Rule 5550(b).
- Compliance Strategy: The company plans to satisfy the Stockholders' Equity Rule (rather than the Minimum Market Value of Listed Securities Rule) by raising capital.
- Capital Raising Targets: The company aims to increase stockholders' equity to over $2.5 million by April 30, 2025, with further increases targeted by July 15, 2025.
Guidance, Outlook, and Risks
Conditions of Extension: The extension is conditional. The company must demonstrate progress on its capital raising plan by specified dates. By August 12, 2025, the company must publicly disclose transactions undertaken to increase equity and provide an update on fundraising plans and income projections for the next 12 months.
Risks and Contingencies:
- Delisting Risk: If the company fails to execute its plan to the Panel's satisfaction, Nasdaq may delist the common stock after April 30, 2025, despite the extension.
- Uncertainty: Management explicitly states that no assurances can be given that the company will successfully raise capital or regain compliance by the deadline.
- Market Impact: Potential delisting could limit demand for the stock, impair the ability to raise additional capital, and adversely affect the market price and trading efficiency.
Investor Verification Checklist
- Verify the company's ability to raise capital to exceed $2.5 million in stockholders' equity by the April 30, 2025 interim deadline.
- Monitor upcoming disclosures regarding specific fundraising transactions and updated income projections required by August 12, 2025.
- Review the risk factors in the Form 10-K filed on March 31, 2025, for detailed information on the consequences of potential delisting.
- Confirm whether the company has elected to pursue the Stockholders' Equity Rule or the Minimum Market Value of Listed Securities Rule for final compliance.